Patents Assigned to Merck Sharp
  • 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES
    Publication number: 20140161770
    Abstract: The present invention relates to 2?-Cyano Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one 2?-Cyano Substituted Nucleoside Derivative, and methods of using the 2?-Cyano Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: April 11, 2012
    Publication date: June 12, 2014
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Vinay Girijavallabhan, F. George Njoroge, Stephane Bogen, Angela Kerekes, Frank Bennett, Ying Huang, Latha Nair, Dmitri Pissarnitski, Vishal Verma, Qun Dang, Ian Davies, David B. Olsen, Andrew Stamford, Joseph P. Vacca
  • PCSK9 immunoassay
    Patent number: 8748115
    Abstract: Methods of using PCSK9 antagonists More specifically, methods for measuring circulating PCSK9 levels in a biological sample by means of an immunoassay The immunoassay used can be a solid phase immunoassay, such as a dissociation-enhanced lanthanide fluorescence immunoassay utilizing an E07 capture antibody or coating and a G08 or H23 detecting antibody.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: June 10, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yan Ni, Ayesha Sitlani, Shilpa Pandit, Dale Lewis, Xun Shen, Sharon Lobo, Timothy McCabe, Jon Condra, Rose Cubbon
  • surface protein SA1789 and protective vaccine based thereon
    Patent number: 8747858
    Abstract: The novel protein SA1789 from Staphylococcus aureus is provided as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Also provided is a composition, particularly a S. aureus vaccine, comprising SA1789 protein or a fragment or derivative thereof capable of generating an immune response that leads to the killing and clearance of S. aureus.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: June 10, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tessie B. McNeely, Hongxia Fan, Mark Andrew Miller
  • ?3 adrenergic receptor agonists
    Patent number: 8748433
    Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of b3-adrenoceptor.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: June 10, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Richard Berger, Scott D. Edmondson, Bart H. Harper
  • Methods for characterizing agonists and partial agonists of target molecules
    Patent number: 8744778
    Abstract: In one aspect, the present invention provides methods of determining whether an agent is more like a partial agonist of a target molecule than a full agonist of the same target molecule. In another aspect, the present invention provides methods to select a candidate compound that may reduce blood plasma glucose concentration in a mammal. Populations of genes are provided that are useful in the practice of the present invention.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: June 3, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yejun Tan, Hongyue Dai, Pek Yee Lum, John Ryan Thompson, Joel Peter Berger, Eric Stanley Muise, Richard F. Raubertas, Kenny Kin Chung Wong
  • Soluble guanylate cyclase activators
    Patent number: 8741910
    Abstract: Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the Formula I.
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: June 3, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Linda L. Brockunier, Jian Guo, Emma R. Parmee, Subharekha Raghavan, Keith Rosauer, Darby Schmidt, John E. Stelmach
  • Drug delivery system
    Patent number: 8741329
    Abstract: The subject invention provides a drug delivery system comprising at least one compartment comprising (i) a drug-loaded thermoplastic polymer core layer, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said core layer is loaded with crystals of a first (pharmaceutically) active compound and said intermediate layer is loaded with, crystals of the second (pharmaceutically) active compound.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: June 3, 2014
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Wouter de Graaff, Raymond Zeeman
  • Spiroxazolidinone compounds
    Patent number: 8742110
    Abstract: Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: June 3, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph L. Duffy, Jianming Bao, Debra L. Ondeyka, Sriram Tyagarajan, Patrick Shao, Feng Ye, Revathi Katipally, Aaron Zwicker, Edward C. Sherer, Michael A. Plotkin, Remond Moningka, Zahid Hussain, Harold B. Wood, Feroze Ujjainwalla, F. Anthony Romero, Paul E. Finke, Yi Zang, Weiguo Liu
  • POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS
    Publication number: 20140147461
    Abstract: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides and compositions thereof. SEQ ID NO: 1 is a full length S. aureus sequence. A derivative of SEQ ID NO: 1 containing an amino terminus his-tag was found to produce a protective immune response against S. aureus.
    Type: Application
    Filed: February 7, 2014
    Publication date: May 29, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Tessie B. McNeely, Leslie D. Cope, Mark A. Miller, Loren D. Schultz, Xinmin Wang
  • USE OF IL-23 ANTAGONISTS FOR TREATMENT OF INFECTION
    Publication number: 20140147442
    Abstract: Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections.
    Type: Application
    Filed: October 28, 2013
    Publication date: May 29, 2014
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Manfred Kopf, Luigina Romani, Robert A. Kastelein, Alissa A. Chackerian
  • Aminopyrimidines as Syk inhibitors
    Patent number: 8735417
    Abstract: The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: May 27, 2014
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Michael D. Altman, Kenneth L. Arrington, Jason Burch, Bernard Cote, Jean-Francois Fournier, Jacques Yves Gauthier, Solomon Kattar, Sandra Lee Knowles, Jongwon Lim, Michelle R. Machacek, Alan B. Northrup, Michael H. Reutershan, Joel S. Robichaud, Adam J. Schell, Kerrie B. Spencer
  • CETP inhibitors
    Patent number: 8735435
    Abstract: Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: May 27, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Joann M. Napolitano, Qiaolin Deng, Zhijian Lu, Peter J. Sinclair, Gayle E. Hallett, Christopher F. Thompson, Nazia Quraishi, Cameron J. Smith
  • Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
    Patent number: 8735604
    Abstract: The present invention relates to compounds of the general formula: (I) wherein ring B, R1, R2, R3, Z, and L1 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: May 27, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Eric J. Gilbert, Michael W. Miller, Duane Eugene DeMong, Andrew W. Stamford, William J. Greenlee
  • Isolated Mammalian Monocyte Cell Genes; Related Reagents
    Publication number: 20140141444
    Abstract: DNA clones encoding a receptor in the Ig superfamily and a related soluble variant have been isolated from a human monocyte library. The invention provides receptor polypeptides, nucleic acids encoding them, expression vectors, and transformed cells for recombinant production of the polypeptides.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips
  • INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
    Publication number: 20140142115
    Abstract: This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.
    Type: Application
    Filed: January 24, 2014
    Publication date: May 22, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Alexander Pasternak, Yuping Zhu, Aurash Shahripour, Haifeng Tang, Lihu Yang, Shawn P. Walsh, Nardos H. Teumelsan
  • Isolated Mammalian Monocyte Cell Genes; Related Reagents
    Publication number: 20140141445
    Abstract: DNA clones encoding a receptor in the Ig superfamily and a related soluble variant have been isolated from a human monocyte library. The invention provides receptor polypeptides, nucleic acids encoding them, expression vectors, and transformed cells for recombinant production of the polypeptides.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips
  • METHODS OF MODULATING CYTOKINE ACTIVITY; RELATED REAGENTS
    Publication number: 20140140954
    Abstract: Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor.
    Type: Application
    Filed: February 3, 2014
    Publication date: May 22, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jochen Schmitz, Martin Oft, Robert A. Kastelein, J. Fernando Bazan
  • ENGINEERED ANTI-TSLP ANTIBODY
    Publication number: 20140141012
    Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders and allergic inflammatory response.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Applicant: MERCK SHARP & DOHME CORP.
    Inventor: Leonard G. Presta
  • Diphenyl substituted alkanes as flap inhibitors
    Patent number: 8729104
    Abstract: The instant invention provides compounds of formula I which are 5-lipoxygenase activating protein inhibitors. Compounds of formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: May 20, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Lin Chu, Ihor E. Kopka, Bing Li, Anthony K. Ogawa, Feroze Ujjainwalla
  • Tricyclic heterocyclic derivatives
    Patent number: 8729274
    Abstract: The present invention relates to a tricyclic heterocyclic derivative according to Formula (I), wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to pharmaceutical compositions comprising said tricyclic heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of serotonin mediated disorders, such as obesity.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: May 20, 2014
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Keneth Davies, Takao Kiyoi, Ashvinkumar Dhirubhai Mistry, Peter Christopher Ray, Mark Reid, Grant Wishart